Pharmacokinetics & PK/PD Modeling
Non-compartmental and compartmental PK/TK analyses, population modeling (Phoenix NLME, Monolix, Simulx), PBPK simulation with GastroPlus®, and human dose prediction for preclinical-to-clinical translation.
Research
Research & Publications
Peer-reviewed scholarship spanning pharmacokinetics, nanomedicine, formulation science, and drug delivery.
- 13Publications
- 816Citations
- 12+Years of Research
- 2Doctoral Degrees
Focus Areas
Research Areas
Nanomedicine & Drug Delivery Systems
Design, optimization, and characterization of novel drug delivery systems including PLGA nanoparticles, transdermal patches, and conventional dosage forms. Expertise in DoE-driven formulation optimization and in vitro dissolution modeling.
Bioanalytical Method Development
Development and validation of quantitative bioanalytical methods across UPLC and triple-quadrupole LC-MS/MS platforms. Proficient in Waters Empower, Sciex OS, and Analyst® for data acquisition and quantitative analysis.
Scholarship
Showing 13 of 13 publications
From Screening to Optimization: Strategic Implementation of Design of Experiments (DOE) for Robust Nanoparticle Formulation.
Polymers 2026, 18, 2034.
Expanding Arsenal against Ocular Diseases through Nanoemulsion: Success So Far and the Road Ahead.
Curr. Drug Delivery 2025, 22, 694–707.
Surfactant Mediated Accelerated and Discriminatory In Vitro Drug Release Method for PLGA Nanoparticles of Poorly Water-Soluble Drug.
Pharmaceuticals 2022, 15, 1489.
Design of Experiment (DOE) for Optimization of PLGA Nanoparticles.
FASEB J. 2022, 36 (Suppl. 1), R6197.
Development and Validation of an LC–MS/MS Method for AC1LPSZG and Pharmacokinetics Application in Rats.
J. Chromatogr. Sci. 2022, 60, 26–34.
In Vitro Dissolution Considerations Associated with Nano Drug Delivery Systems.
Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2021, 13, e1732.
Nanoparticles in Daily Life: Applications, Toxicity and Regulations.
J. Environ. Pathol. Toxicol. Oncol. 2018, 37, 209–230.
Clinical Success versus Attrition of Investigational Pharmaceuticals: A Vignette.
Crit. Rev. Ther. Drug Carrier Syst. 2017, 34, 527–549.
Formulation Optimization of Tizanidine Hydrochloride Nanoparticles Using 3² Factorial Designs.
Int. J. Pharma Bio Sci. 2016.
Preparation and Physicochemical Characterization of Tizanidine Hydrochloride Nanoparticles.
J. Pharm. Res. 2013, 12, 15–22.
Influence of Formulation Parameters on Tizanidine Hydrochloride Nanoparticles.
Int. J. Pharma Bio Sci. 2013, 4, 1056–1078.
Role of Nanotechnology in Healthcare System Management.
Int. J. Pharm. Res. Bio-Sci. 2013, 2, 375–406.
Formulation and In Vitro Evaluation of Transdermal Drug Delivery System of Tizanidine Hydrochloride.
J. Pharm. Res. 2008, 7, 208–213.
Let's Work Together
Whether you are seeking a research collaborator, a pharmacokinetics consultant, or an independent scientific expert — I welcome substantive conversations about meaningful work.
Get in Touch